The prognosis of treated epilepsies has improved over the last 20 years. Some authors have reported an overall remission rate of 60-80% with wide differences depending on the type of epilepsy. The extent of patients' response to therapy becomes evident in the first two years of treatment. In 30% of cases, remission is unstable. We discuss how to define therapy response in practical terms. In recently diagnosed adult patients, monotherapies prove effective in 80% of cases. Addition of a second drug only appears warranted in 10-15% of uncontrolled patients. In chronic patients defined as drug-resistant it may be useful to reconsider monotherapy at high doses or different drug combinations.
|Title of host publication||Bollettino - Lega Italiana contro l'Epilessia|
|Number of pages||4|
|Publication status||Published - 1988|
ASJC Scopus subject areas
- Clinical Neurology